Clinical Trials:

The Key to Advancing Brain Tumor Treatment

We are very excited – and encouraged – about our participation in a potentially game-changing brain cancer vaccine. The “SURVIVE” Phase 2B trial enables our team to treat newly diagnosed glioblastoma patients with SurVaxM. This first-of-its-kind vaccine targets survivin, a cell-survival protein found in 95% of glioblastomas and many other cancers. Overlook Medical Center is the only site in New Jersey and one of the first three in the nation to participate in this trial.

We are also involved in a study of Berubicin in adults with recurrent glioblastoma multiforme. Berubicin is part of a class of chemotherapy agents that leverages natural processes to damage an enzyme that allows cancer cells to spread. This agent is one of the first to cross the blood-brain barrier and overcome drug resistance.

We are also involved in developing novel treatments such as immunotherapies, CAR-T strategies, oncolytic tumor viruses and other targeted therapies for:

  • Low-grade gliomas
  • Other high-grade primary brain tumors
  • Metastatic brain tumors
  • Tumors that cause malignant cells to spread to the fluid surrounding the brain and spinal cord (leptomeningeal cancer)

Please call 908-522-5768 to get more information about our clinical trials.

Brain Tumor Support Groups

Patients, family members and caregivers are invited to participate in the Glasser Brain Tumor Center’s support group. During our hour-long, monthly, virtual meetings hosted by our clinical staff members, attendees share, learn and grow together.

To learn more about our support group and how you or a loved one can benefit, please contact Janet LeMonnier at or call 908-522-5159.